What is Lifesci Capital's Estimate for AVBP FY2025 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Lifesci Capital dropped their FY2025 earnings per share estimates for shares of ArriVent BioPharma in a research report issued to clients and investors on Monday, March 3rd. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($3.97) per share for the year, down from their prior estimate of ($3.80). The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma's FY2026 earnings at ($4.49) EPS.

Several other research firms have also weighed in on AVBP. HC Wainwright reissued a "buy" rating and set a $39.00 price objective on shares of ArriVent BioPharma in a research note on Friday. Guggenheim started coverage on ArriVent BioPharma in a research report on Monday. They issued a "buy" rating and a $45.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $39.40.

ArriVent BioPharma Trading Down 0.6 %

AVBP stock traded down $0.14 on Thursday, hitting $21.73. 112,059 shares of the company's stock traded hands, compared to its average volume of 166,079. The stock has a market cap of $739.17 million, a price-to-earnings ratio of -8.46 and a beta of 1.00. ArriVent BioPharma has a 1-year low of $14.35 and a 1-year high of $36.37. The stock has a fifty day moving average of $26.10 and a 200-day moving average of $27.11.

Remove Ads

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.18.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its position in ArriVent BioPharma by 153.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company's stock worth $4,756,000 after purchasing an additional 122,641 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of ArriVent BioPharma during the 3rd quarter worth approximately $240,000. FMR LLC boosted its holdings in ArriVent BioPharma by 8.7% during the third quarter. FMR LLC now owns 2,119,695 shares of the company's stock worth $49,813,000 after buying an additional 169,514 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in ArriVent BioPharma by 32.6% during the third quarter. BNP Paribas Financial Markets now owns 21,965 shares of the company's stock worth $516,000 after acquiring an additional 5,397 shares in the last quarter. Finally, MetLife Investment Management LLC increased its position in shares of ArriVent BioPharma by 168.9% during the third quarter. MetLife Investment Management LLC now owns 16,350 shares of the company's stock worth $384,000 after acquiring an additional 10,269 shares in the last quarter. Hedge funds and other institutional investors own 9.48% of the company's stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.